Stay updated on T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version of a clinical study on the efficacy of talimogene laherparepvec combined with pembrolizumab for treating metastatic and locally advanced sarcomas, with changes in the study's revision number and the principal investigator's name.SummaryDifference52%
- Check29 days agoChange DetectedThe webpage has updated its version from v2.14.3 to v2.14.4 and has added new dates for 2025, while removing previous dates from 2024 and 2025.SummaryDifference1.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.